Literature DB >> 22333853

Generic versus brand-name North American topical glaucoma drops.

Zaid N Mammo1, John G Flanagan, David F James, Graham E Trope.   

Abstract

OBJECTIVE: To determine whether brand-name glaucoma drops differ from generic equivalents in bottle design, viscosity, surface tension, and volume in North America.
DESIGN: Experimental study. PARTICIPANTS: We studied 5 bottles each of 11 kinds of glaucoma drops.
METHODS: Density-based calculations of drop volume were assessed using 0.1 mg analytic balance. Viscosity was measured using rotational rheometery. Bottle tip diameter was measured using 0.05 mm Vernier calipers. Surface tension was measured using a Fisher Scientific (Ottawa, ON) tensiometer.
RESULTS: For the American brand-name Timoptic XE, the average drop volume was 38 ± 3.1 μL versus 24 ± 1.5 μL of Timolol GFS (p < 0.0001). For the Canadian brand-name Timoptic XE, the average drop volume was 42 ± 4.0 μL versus 25 ± 2 μL of timolol maleate EX (p < 0.0001). The Canadian brand-name Timoptic drop volume was 28 ± 1.4 μL versus 35 ± 1.9 μL Apo-Timop (p < 0.01). At a 0.1 per second shear rate, the viscosity of Canadian Timoptic XE was 20 times higher than that of its generic equivalent, whereas the viscosity of American Timoptic XE differed from the generic by a factor of 100. The surface tension of Canadian Timoptic XE was 31% higher than that of the generic (p < 0.001), whereas the surface tension of American Timoptic XE was 21% higher than that of the generic (p < 0.001). The bottle tips of the Canadian and American Timoptic XE measured about 3.5 times larger than those of their generics.
CONCLUSION: American and Canadian Timoptic XE eye drops vary significantly from the generics in drop volume, viscosity, surface tension, and bottle tip. Canadian brand-name Timoptic delivered significantly smaller drop volumes than generic Apo-Timop. Careful consideration should be given to drop viscosity and bottle design when generic ophthalmic products are evaluated for interchangeability and market entry.
Copyright © 2012 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22333853     DOI: 10.1016/j.jcjo.2011.12.004

Source DB:  PubMed          Journal:  Can J Ophthalmol        ISSN: 0008-4182            Impact factor:   1.882


  12 in total

1.  [Original preparations versus generics--latanoprost: how similar is different?].

Authors:  M A Leitritz; H-P Lipp; B Voykov; F Ziemssen
Journal:  Ophthalmologe       Date:  2015-02       Impact factor: 1.059

2.  Effect of Particle Size and Viscosity of Suspensions on Topical Ocular Bioavailability of Budesonide, a Corticosteroid.

Authors:  Sunil Vooturi; David Bourne; Jiban Jyoti Panda; Stephanie Choi; Hyewon Kim; Sarath K Yandrapu; Uday B Kompella
Journal:  J Ocul Pharmacol Ther       Date:  2020-07-14       Impact factor: 2.850

Review 3.  Pediatric Glaucoma: Pharmacotherapeutic Options.

Authors:  Monica Samant; Anagha Medsinge; Ken K Nischal
Journal:  Paediatr Drugs       Date:  2016-06       Impact factor: 3.022

4.  Comparison of United States and canadian glaucoma medication costs and price change from 2006 to 2013.

Authors:  Matthew B Schlenker; Graham E Trope; Yvonne M Buys
Journal:  J Ophthalmol       Date:  2015-04-01       Impact factor: 1.909

Review 5.  Evaluation of Physical Properties of Generic and Branded Travoprost Formulations.

Authors:  Meenakshi Wadhwani; Sanjay K Mishra; Dewang Angmo; Thirumurthy Velpandian; Ramanjit Sihota; Ankita Kotnala; Shibal Bhartiya; Tanuj Dada
Journal:  J Curr Glaucoma Pract       Date:  2016-08-05

Review 6.  Medical Management of Glaucoma in the 21st Century from a Canadian Perspective.

Authors:  Paul Harasymowycz; Catherine Birt; Patrick Gooi; Lisa Heckler; Cindy Hutnik; Delan Jinapriya; Lesya Shuba; David Yan; Radmila Day
Journal:  J Ophthalmol       Date:  2016-11-08       Impact factor: 1.909

7.  Bottle Characteristics of Topical International Glaucoma Medications versus Local Brands in Saudi Arabia.

Authors:  Nasser Al-Jumaian; Rizwan Malik; Rajiv Khandekar; Abdullah Al-Humaidan; Rana Al-Madany; Reham Al-Qahtani; Ahmed Altowairqi; Abdulwahab Al-Theeb; Babar Zaman; Leyla Al-Djasim; E Randy Craven; Deepak P Edward
Journal:  Middle East Afr J Ophthalmol       Date:  2016 Oct-Dec

8.  European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition - Chapter 3: Treatment principles and options Supported by the EGS Foundation: Part 1: Foreword; Introduction; Glossary; Chapter 3 Treatment principles and options.

Authors: 
Journal:  Br J Ophthalmol       Date:  2017-06       Impact factor: 4.638

9.  North American cost analysis of brand name versus generic drugs for the treatment of glaucoma.

Authors:  Monali S Malvankar-Mehta; Lucy Feng; Cindy Ml Hutnik
Journal:  Clinicoecon Outcomes Res       Date:  2019-12-16

Review 10.  Substandard drugs: a potential crisis for public health.

Authors:  Atholl Johnston; David W Holt
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.